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Abstract
Background As reimbursement authorities are gaining greater
power to influence the prescription behavior of physicians, it
remains critical for life science companies focusing on per-
sonalized medicine to develop “tailor-made” payer engage-
ment strategies to secure reimbursement and assure timely
patient access to their innovative products. Depending on the
types of such engagement, pharmaceutical and diagnostic
companies may benefit by obtaining access to medical and
pharmacy claims data, getting invaluable upfront inputs on
evidence requirements and clinical trial design, and strength-
ening trust by payers, therefore avoiding uncertainties with
regards to pricing, reimbursement, and research and develop-
ment reinvestment. This article aims to study the evolving
trend of partnering among two interdependent, yet
confronting, stakeholder groups—payers and producers—as
well as to identify the most promising payer engagement strat-
egies based on cocreation of value introduced by life science
companies in the past few years. We analyzed the recent case
studies from both therapeutic and diagnostic realms consid-
ered as the “best practices” in payer engagement. The last
5 years were a breakout period for deals between life science
companies and reimbursement authorities in the area of per-
sonalized medicine with a number of felicitous collaborative
practices established already, and many more yet to emerge.
We suggest that there are many ways for producers and payers
to collaborate throughout the product life cycle—from data
exchange and scientific counseling to research collaboration
aimed at reducing healthcare costs, addressing adherence is-
sues, and diminishing risks associated with future launches.
Conclusions The presented case studies provide clear insights
on how successful personalized medicine companies custom-
ize their state-of-the-art payer engagement strategies to ensure
closer proximity with payers and establish longer-term trust-
based relationships.
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Background
The emergence of comparative effectiveness research and the
shift of the healthcare industry toward novel outcome-based
payment models have put diagnostic and pharmaceutical com-
panies in a less convenient, yet propitious, position in person-
alized (and so-called precision) medicine. On one hand, the
need to provide convincing evidence for the superiority of
therapeutic, diagnostic, or drug delivery solutions over the
existing alternatives has escalated developmental costs and
created additional market access complexities. On the other
hand, companies that are able to justify the value of their
products by demonstrating a measurable differentiation
vis-à-vis competitors have a luxury to enjoy high premiums
and gain unique competitive advantage to a large extent due to
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more extensive reimbursement and wider stakeholder
acceptance.
Considering heterogeneity of stakeholder needs, diversity
of tools to quantify value of products, and breadth of possible
clinical and nonclinical evidence, it remains critical for inno-
vative companies with focus on personalizedmedicine to part-
ner with institutional customers, particularly payers, to create
the aligned incentives and support the necessary capabilities to
make value-based deals work. Depending on the types of such
collaboration, life science companies may benefit by
obtaining access to medical and pharmacy claims data, getting
invaluable upfront inputs on evidence requirements and
clinical trial design, and strengthening trust by payers, there-
fore avoiding uncertainties with regards to pricing and
reimbursement.
The recent survey conducted among 75 managed care ex-
ecutives in the USA showed that partnering between payers
and biopharma becomes a prevailing wind in the industry with
more than 70% of respondents recognizing value in the early
stage collaboration [1]. Notwithstanding that payers recognize
the vitality of pharma data presented upfront, only 31% of the
payers claim to take part in phase III clinical trials, and less
than a quarter involve in the earlier phase testing. The reasons
for such discrepancy are multifold: lack of trust in manufac-
turers, pharma’s underestimation of the importance of early
stakeholder engagement, and even more so the inability of
the industry to navigate the two topmost payer challenges—
compliance and cost containment.
The aforementioned signifies that there is a clear gap in the
way the industry and payers interact, making it exceedingly
difficult for both parties to realize the full potential of their
convergence. However, it also implies the tremendous oppor-
tunities for pharmaceutical and diagnostic companies focusing
on precision medicine to address this gap by designing and
implementing more sophisticated precompetitive programs
involving payers in the mature and fast-growing markets.
This paper aims to study the evolving trend for partnering
among the two interdependent, yet confronting, stakeholder
groups—payers and producers—as well as to identify the
most promising payer engagement strategies based on
cocreation of value introduced by companies with focus on
personalized medicine in the past few years.
The growing influence of payers and innovation
crisis
The dramatic spike in healthcare costs over time has put an
enormous pressure on payers to toughen the reimbursement
criteria for pharmaceutical and diagnostic products in the de-
veloped and emerging markets. Exerting greater influence on
the global healthcare ecosystem, payers (governments, phar-
macy benefits managers, public and private insurance plans,
and managed care organizations) have set up an unspoken rule
that obtaining FDA, EMA, or CE approval no longer provides
the life science companies with a privilege to charge premium
prices and secure reimbursement.
Today, reimbursement authorities are demanding addition-
al evidence that goes far beyond the customary safety and
efficacy data, incorporating relative cost-effectiveness
and budget impact analyses in their formulary decisions.
As a result, innovative companies continue suffering from
intense drop-offs in positive decisions for new product
reimbursement.
Thus, out of 102 cancer drug indications appraised by the
National Institute for Health and Care Excellence (NICE) be-
tween 2007 and 2014, only 47 (46%) were fully or partially
recommended for NHS commissioning [2]. Similar numbers
were observed in Germany in the period of 2011–2014, where
Institute for Quality and Efficiency in Health Care (IQWIG)
determined that 50% of the assessed new drugs offered “no
additional benefit” vis-à-vis comparators [3]. Moreover, sub-
stantial private and public reimbursement rejections were ev-
idenced among molecular diagnostic and therapeutic compa-
nies in the USA and Australia particularly due to the inability
to justify value-for-money [4, 5].
Recognizing the growing influence of payers and account-
ing for the direct correlation of insurance premiums with the
escalating medicinal costs, large medical societies, such as
American Society of Clinical Oncology (ASCO) and
American Heart Association (AHA), are now considering on
incorporating costs or “financial toxicity” as another impor-
tant perspective in the guidelines [6, 7]. The rise in healthcare
expenditure has also created much anxiety amid physicians in
the countries where retirement benefit or other financial incen-
tives are affected by overprescribing [8]. With pressure from
public and private payers, the cost-sensitive prescribers be-
come less and less influential in their clinical decisions often
giving preferences to cheaper and less effective options over
highly effective therapeutics and diagnostics that are not cov-
ered by health plans.
For example, in the Netherlands, 75% of the total drugs
(including Herceptin®) in about 1/3 of the Dutch hospitals
were uncovered by the healthcare insurance in the mid-
2000s, leading to unequal access to highly effective and costly
medicines [9]. And it is only the 7-year Herculean effort of the
two patient advocacy groups—the Dutch Breast Cancer
Association and the Dutch Federation of Cancer Patient
Organizations—that changed the status quo of Herceptin®,
even though the final impact on the cost control and reim-
bursement procedures in the Netherlands were still not
achieved.
While the economic expediency and ethics associated with
payer-guided healthcare provision are not that straightforward
and are always subject to lengthy debates, it is quite obvious
and particularly critical that a significant undervaluation of
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diagnostics and therapeutics by means of severe pricing and
reimbursement restrictions leads to an underincentivized in-
novation. According to Thomson Reuters and Deloitte joint
survey, the cost of bringing a new medicine from discovery to
launch has escalated fromUSD 1.1 billion in 2010 to USD 1.3
billion in 2013 (+18%). Moreover, the burden of late stage
failures was estimated to deprive the top 12 pharma compa-
nies of USD 243 billion in 2010–2013 [10].
As innovative companies prioritize their portfolios based
on commercial expectations, health insurance reimbursement
levels are the key economic signals for innovators to deter-
mine whether the likely market for a new diagnostic or thera-
peutic will be large enough to substantiate costly investments.
Hence, bearing high marginal costs and getting low incentives
from payers, today, profit-driven innovative companies be-
come more rigid in revising their pipeline assets in terms of
reimbursement attractiveness, frequently limiting patient ac-
cess to high-quality products for fear of a coverage fiasco.
Thus, in the early 2000s, several large pharmaceutical com-
panies have abandoned antibiotics research and investment
prioritizing drugs in other classes, such as cancer and heart
disease. This resulted in the fact that resistance to existing
medicines continued to increase, while the number of new
antibiotics receiving FDA approval declined [11, 12]. In
2014, the problem was addressed by the President’s Council
of Advisors on Science and Technology that assembled mis-
cellaneous stakeholders to create new aligned incentives facil-
itating research and development (R&D) in antibiotics [13].
All of these suggest that the current approach to healthcare
coverage is imbalanced and, in light of the growing influence
of payers, it is crucial to revise the way “innovation” is defined
and valuated, outlining unambiguous incentives for the life
science companies to continue reinvesting into R&D.
“Per aspera ad astra”—innovative payer
engagement strategies
In the past several years, the life science companies have been
responsive to the new payer role by means of expanding their
market access and regional sales teams to target the specific
reimbursement accounts, collecting more data on payer “pain
points” and decision-making processes, customizing core val-
ue dossiers to the local payer needs, and allocating substantial
funds on localized real-world evidence studies. Although im-
portant, these strategies provide companies with only incre-
mental benefits, and do not allow the necessary proximity
with reimbursement authorities. Hence, to achieve such prox-
imity, companies should havemore open dialogues and tighter
collaboration with payers based on trust and cocreation of
value (Fig. 1).
Reimbursement authorities, uncertain of what manufac-
turers have in their pipelines, generally appreciate early
dialogues with the life science companies to be more informed
about impending launches and the associated additional bud-
get loads. In response, companies are able to address their
questions and create more clarity on what they can do to make
the pipeline and marketed therapeutics more attractive from a
payer perspective. Yet, despite of market access and commer-
cial teams creating a myriad of brilliant ideas on how to part-
ner with reimbursement authorities, there are always ethical
and regulatory constraints about going beyond the conven-
tional unit price-based relationships and co-pays. One of the
prime concerns of the healthcare stakeholders regarding the
industry–payer partnerships is transparency.
To address this issue and to harmonize early dialogues
between HTA agencies and the producers of health technolo-
gies, recently, there has been launched a new initiative in
Europe called “Shaping European Early Dialogue” (SEED)
[14]. This pilot consortium, led by the French Haute
Autorité de Santé (HAS) and financed by the European
Commission (EC), is currently covering 10 projects (7 for
therapeutics and 3 for medical devices), which will facilitate
the development of methodological guidelines on the early
stage payer–producer interaction.
A number of legislative acts incentivizing industry–payer
convergence have also appeared at a national level. For exam-
ple, in the UK, the Health and Social Care Act of 2012 has
introduced a framework to encourage collaboration between
the National Health Service and life science companies aimed
at facilitating innovation and healthcare delivery [15].
The early dialogues between manufacturer and reimburse-
ment authorities are particularly important in light of the
existing inconsistencies in the way “innovation” is defined
by both parties. It frequently occurs that producers consider
“me-too” medicines as innovative because of their distinct
manufacturing process and differences in the mechanism of
action vis-à-vis the standard of care. On the contrary, reim-
bursement authorities pay more attention to the overall com-
parative effect of a therapeutic versus the associated costs, and
little are they interested in the surrogate endpoints or techno-
logical peculiarities of an innovative product.
According to Bach (2009), prices of the majority of anti-
cancer therapeutics are escalating with greater velocity than
the health benefits associated with them, making each treat-
ment progress less cost-effective than the previous one [16].
Having no ultimate way to assess the true value of innovation,
payers are guided by a simple principle that innovation with-
out a strong differentiation should not be included in their drug
formularies, while a unique therapeutic or diagnostic solution
with greater relative effectiveness targeting a high unmet need
is more likely to see the reimbursement green light.
Yet, the borderline between “strong” and “weak” differen-
tiation varies greatly between HTA and reimbursement au-
thorities, making it literally impossible to adequately quantify
innovation. For example, the recent study conducted by
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Droeschel et al. showed that of the 20 identical oncology
therapies evaluated by French and English HTA bodies, 17
have been recommended by HAS, and only 4 received posi-
tive decisions by NICE [17].
As suggested by Fig. 1, apart from early dialogues with
companies, payers recognize substantial value in almost all
kinds of research initiatives related to cost mitigation—from
participation in real-world evidence studies to engagement in
a comparative effectiveness research. For example, in 2009–
2011, Medco Health Solutions (acquired by Express Scripts)
has launched a large head-to-head study of Plavix®
(clopidogrel) and Effient® (prasugrel) stretching out over
2 years to identify the strata of heart patients, who were not
able to metabolize clopidogrel and required to be switched to
prasugrel based on their genetic makeup [18]. Thus, being
able to direct patients to less expensive generic versions of
clopidogrel, the pharmacy benefit manager acquired more
confidence that it had achieved comparable care at a signifi-
cantly reduced cost.
Along the same lines, in 2011 AstraZeneca has signed
an agreement with WellPoint’s HealthCore to establish a
4-year evidence of development partnership generating
real-world data via prospective and retrospective observa-
tional studies on the most effective and economical treat-
ments in chronic and other diseases [19]. As a part of this
deal, companies were to analyze electronic medical re-














































Fig. 1 Examples of innovative
payer engagement strategies in
personalized medicine
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Another attractive area for life science companies to col-
laborate with reimbursement authorities is poor medication
adherence, which is perhaps the hottest issue faced by payers
these days along with cost containment. Hence, by leveraging
innovative patient-centered solutions (e.g., financial incen-
tives, telemedicine, e-pills, m-health, user-friendly drug deliv-
ery devices, and improving healthcare delivery) companies
are able to win trust and create greater value for payers.
The Merck–Cigna collaboration on Januvia® and
Janumet® is one of the successful industry–payer partnership
examples resulting in 87% improved patient adherence to
therapy, in whichMerck introduced large discounts to patients
who followed the medication regime as prescribed, and Cigna
lowered co-pay levels for adhering patients [8]. Another case
of WellDoc’s BlueStar also perfectly illustrates how a mobile-
integrated therapy coupled with electronic health records en-
ables adults with type 2 diabetes to achieve statistically sig-
nificant improvements in HbA1c level, enhance patient satis-
faction and win reimbursement [20, 21].
Establishing risk-sharing agreements (also, “managed en-
try agreements,” “patient access schemes,” “RSAs,” “MEAs,”
and “PAS”) is another broadly utilized approach to engage
with payers, for such arrangements offer the potential for ear-
lier access to new therapeutics and diagnostics by linking re-
imbursement levels to real-world performance or use of a
product. RSAs aim at sharing financial risks due to uncertainty
related to the introduction of new technologies [22].
There are three major groups of RSAs [23]:
1) Financially based schemes define producer’s contribu-
tions to the cost of a therapeutic or diagnostic based on
financial thresholds, and not linking coverage to health
outcomes (e.g., price–volume agreements, rebates, dis-
counts, and utilization caps);
2) Outcome-based schemes are performance-based agree-
ments, in which health-related quality of life predeter-
mines pricing and reimbursement levels (e.g., pay-for-
performance, outcomes guarantee, and disease manage-
ment schemes);
3) Evidence-based schemes (also, “coverage with evidence
development” or “CED”) are a category of industry–pay-
er deals, in which a company is granted temporary reim-
bursement in exchange for generation of supplementary
real-world evidence with the subsequent revision of cov-
erage conditions based on the collected evidence.
According to Ferrario and Kanavos, Belgium, England,
Sweden, and the Netherlands had 133 active RSAs as of
2012, with English payers giving preferences to discounts
and free doses; Dutch prioritizing CED; Swedes considering
CED, monitoring utilization and compliance with restrictions
via observational studies; and Belgians equally using all of the
aforementioned practices [24]. The utilization of RSAs is also
gaining momentum in the Asia-Pacific region with 98
schemes observed in Australia, 5 in New Zealand and 3 in
South Korea [23]. The emergence of such innovative ap-
proaches to market access is an imperative milestone in for-
mulating new generation payer–producer agreements based
on open dialogue, cooperation, and multi-stakeholder value
creation.
Among other premises for the industry and payers to col-
laborate is the fact that reimbursement authorities are under-
staffed, budget-constrained and bogged down in their routine,
often underperforming in the areas of disease management,
data analysis, as well as patient and provider education [25].
Hence, there are tremendous opportunities for these stake-
holders to partner filling the aforementioned gaps on account
of a disease-specific expertise and resources.
For instance, last year, Novo Nordisk has launched an ini-
tiative called cities changing diabetes, where it partnered with
a number of large private insurers, like United Healthcare,
Blue Cross Blue Shield, Aetna, and Cigna, to tackle the prob-
lem of urban diabetes in the USA, analyzing key factors that
drive the global pandemic and utilizing that knowledge to
shape real-world solutions [26]. Likewise, in 2011, Pfizer
teamed up with Humana to bring together data and scientific
information to create a better comprehension of patient needs
and drug effectiveness [27].
To sum up, there are numerous opportunities for producers
and reimbursement authorities to collaborate based on the
unmet payer needs, including the necessity to reduce
healthcare costs, poor adherence, high uncertainty and risks
associated with future launches, and lack of specific expertise
and resources. Successful life science companies that are able
to customize their state-of-the-art payer engagement strategies
to these needs may achieve closer proximity with payers and
establish longer-term trust-based relationships.
Case studies
The last 5 years were a breakout period for deals between life
science companies and reimbursement authorities in the area
of personalized medicine with a number of felicitous collabo-
rative practices established already, and many more yet to
emerge. Below are several case studies from both therapeutic
and diagnostic realms, considered as the “best practices” in
payer engagement:
“Roche–Swiss Re” collaboration in China
Roche is a global healthcare company developing innovative
therapeutic and diagnostic products in the areas with unmet
medical needs. As of 2014, three out of ten best-selling block-
buster medicines in oncology were developed and commer-
cialized by Roche [28].
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In 2010, the company lined up with Swiss Re to strengthen
its presence in the Chinese market by introducing risk-sharing
deals to local insurers. Since direct commerce of foreign retail
insurance was prohibited by law in China, Roche and Swiss
Re came up with a revolutionary idea to start selling reinsur-
ance, and thus convincing Chinese insurers to offer coverage
for high-quality cancer therapeutics. As a part of this collabo-
ration, Roche provides Swiss Re and local insurers with mar-
keting support and statistical data on different types of cancer,
while Swiss Re provides Chinese insurance companies with
reinsurance and technical support on the product design and
pricing [29].
Within just 2 years, the Roche–Swiss Re collaboration in
China allowed the local insurance policy holders, including
CPIC Life, to achieve their first milestone—selling insurance
to 6 million customers—thus facilitating access of a large
number of cancer patients to innovative treatments, like
trastuzumab [30, 31].
“VitrOmics–CZ–CPCT” partnership in the Netherlands
VitrOmics Healthcare Holding is an organization specialized
in personalized medicine focusing on the development of di-
agnostic products to measure kinase and nuclear receptor ac-
tivities, based on the PamChip® platform created by its
daughter company PamGene.
In the early 2012, the company launched a private–public
collaborative initiative engaging with the Dutch health insur-
ance provider CZ and the Centre for Personalized Cancer
Treatment with the goal to address the problem of overtreat-
ment in breast cancer, providing much more selective therapy
to a stratified subpopulation of patients than stipulated by the
usual clinical practice [32].
As a result, the triad was awarded a value-based healthcare
prize under the patronage of an honorary chairmanMichael E.
Porter, establishing a benchmark for “good practice” in indus-
try–payer partnerships based on cocreation of value and trust.
This initiative has also prepared the ground for two subse-
quent trials in lung and esophageal cancer.
“Eli Lilly–Humana” initiative in the USA
Eli Lilly is a global biopharmaceutical company with primary
focus on noncommunicable chronic diseases and nearly a cen-
tury of experience in diabetes research.
In 2013, the company announced joint research collabora-
tion with a large healthcare insurance company, Humana, in
order to conduct a retrospective analysis of medical, pharma-
cy, and laboratory claims data with the primary objective—to
identify modifiable characteristics of diabetic patients associ-
ated with increased healthcare costs, as well as to study ther-
apeutic interventions affecting patients’ adherence and out-
comes [33].
This data will enable Eli Lilly design more targeted thera-
peutic interventions and disease management programs in the
future, and assist Humana in addressing adherence and cost
issues in diabetes. Similar research initiatives were also intro-
duced by Pfizer, Merck, AstraZeneca, and other companies,
tightly collaborating with leading health insurance providers
[27].
“MolecularMD–Medco” partnership in the USA
MolecularMD is a manufacturer of molecular diagnostic tests
for oncology applications, including a qRT-PCR assay tomea-
sure BCR-ABL levels prior to initiation of chronic myeloid
leukemia (CML) therapy. The Philadelphia chromosome
(BCR-ABL) is found in 95% of CML patients and is currently
considered to be the primary cause of the disease [34, 35].
In 2011, the US leading pharmacy benefit manager Medco
Health Solutions has launched a program titled “DNA
Direct® by Medco™” in collaboration with MolecularMD
to identify patients eligible for treatment, thereby reducing
costs for treating patients that are not responsive [35].
This collaborative patient-centered initiative led to a signif-
icant reduction in healthcare costs for Medco, increased mar-
ket share and revenues of MolecularMD, improved decision-
making of physicians, and enhanced the quality of care of
patients. Apart from the CML program, Medco has also
signed partnerships with other life science companies to iden-
tify patients eligible for warfarin, clopidogrel, tamoxifen,
abacavir, and maraviroc.
“Nuo Therapeutics–CMS” risk-sharing deal in the USA
Nuo Therapeutics is a biomedical company developing and
commercializing individualized regenerative wound-healing
therapies. The company’s flagship product is Aurix®, an au-
tologous hematogel used to treat diabetic foot, pressure, and
venous leg ulcers.
In 2010, facing a national noncoverage determination on
blood-derived products for chronic nonhealing wounds, Nuo
Therapeutics has initiated a dialogue with the Centers for
Medicare & Medicaid Services (CMS) on how to abolish this
national mandate for Aurix®, considering the robust safety
and effectiveness profile of its product [36]. In 2011, the man-
date for Aurix® was removed, yet the CMS concluded that
although promising, the provided data was not sufficient to
validate the product’s generalizability to the Medicare popu-
lation, hence, additional real-world evidence would have been
required for Aurix® to be included in the positive reimburse-
ment list. In 2014–2015, after the approval of protocols for
launching the three prospective randomized effectiveness tri-
als, the positive CED decision was granted to Nuo
Therapeutics [37].
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Global pricing policies
Currently, we observe the debate on global pricing policies in
particular to develop essential medicines and ensure its afford-
ability and availability in the longer term for a consistent sup-
ply in developing countries, like antiretrovirals, artemisinin
combination therapies, drug-resistant tuberculosis medicines,
liposomal amphotericin B (for visceral leishmaniasis), and
pneumococcal vaccines, and to promote policies that “de-
link” the financing of R&D from the price of medicines [38].
The role of international alliances, not-for-profit enter-
prises, is constantly increasing, e.g., the contribution of
Global Alliance for Tuberculosis Drug Development (TB
Alliance) to a public–private partnership, that draws upon
the resources of both private and public institutions to help
address this urgent health need aims to stop the spread of
tuberculosis by developing new, faster-acting, and affordable
tuberculosis drugs [39]. The Global Fund [40] works to sup-
port programs of prevention, treatment, and care for AIDS,
tuberculosis, and malaria and to strengthen health systems.
Eligible countries can receive an upfront allocation, which
provides improved predictability of funding. Starting from
the country’s national strategic plan, stakeholders participate
in an ongoing and inclusive country dialogue.
The several examples of the so-called “philanthrocapitalism”
that include private initiatives/efforts of Bill and Melinda Gates
[41] and Chan Zuckerberg Initiative (CZI) [42] demonstrate fair
success andmight becomemore important player to help fighting
challenging inequalities in healthcare funding in the future.
Horizon 2020 and personalizing health and care
During the first 4 years of Horizon 2020 (work programs for
2014/2015 and 2016/2017), the EU research funding program
Horizon 2020 (2014–2020) and in part icular the
Commission’s proposal for health, demographic change, and
wellbeing challenge [43] will invest more than €2 billion in
calls for proposals or actions considered as an investment in
better health for all, aims to support the development of new,
safer, and more effective interventions to test and demonstrate
new models and tools for health and care delivery and also
contributes to the sustainability of health and care systems [43,
44].
Granting schemes of the European Commission, like the
largest public–private initiative innovative medicines initia-
tive (IMI) [45] with a total budget of €130 million aiming to
speed up the development of better and safer medicines for
patients addresses therapy and diagnostic development chal-
lenges to develop novel solutions for unmet market needs.
Thus, relevant Horizon 2020 calls like “The development
of new methods and measures for improved economic evalu-
ation and efficiency measures in the health sector” focus
on economic model development [46]; EU funding for
precommercial procurement (PCP) and public procurement
of innovative solutions (PPI) projects are available across the
different 2016–2017 Horizon 2020 work programs [47] over-
coming barriers in precompetitive public procurements of in-
novative solutions in particular from SMEs.
This case study signifies the importance of early dialogues
with payers. Yet, it also demonstrates that although Nuo
Therapeutics was rewarded for its persistence and collabora-
tive approach to CMS, much time and financial resources
could have been saved, should the company establish the di-
alogue with the reimbursement authority earlier in the devel-
opmental phase.
Conclusions
Reimbursement authorities, substantially free from regulatory
constraints and driven by the escalating healthcare expendi-
tures, are gaining greater power to impact the prescription
behavior of physicians. Although the payers’ attempts to con-
tain healthcare costs may have a positive economic effect from
a national health service perspective, it may also have a neg-
ative clinical affect from an individual patient perspective, due
to restricted coverage of effective premium-priced products
(direct impact), as well as via underincentivization of innova-
tion (indirect impact).
In the past several years, the life science companies have
been responsive to the new payer role by redesigning sales and
market access teams, adjusting and localizing their clinical
and pharmacoeconomic studies in accordance with the identi-
fied payer requirements, as well as conducting more research
on payer needs. Considering that these strategies provide
pharmaceutical and diagnostic companies with only incre-
mental benefits, producers are advised to have more open
dialogues with payers upfront and to establish tighter collab-
orative initiatives with reimbursement authorities based on
trust and cocreation of value.
There are many ways for producers and payers to collabo-
rate throughout the product life cycle—from data exchange
and scientific counseling to research collaboration aimed at
reducing healthcare costs, addressing adherence issues, and
diminishing risks associated with future launches. Successful
life science companies that are able to design their state-of-
the-art payer engagement strategies around payer needs may
achieve closer proximity with these stakeholders and establish
longer-term trust-based relationships.
Gazing into the future, scenarios in which payers invest
into the life science companies to develop “tailor-made” ther-
apeutic or diagnostic products seem not to be that far off,
although the ethical and legal concerns associated with such
practices are also likely to emerge. Moreover, we anticipate a
greater number of early dialogue initiatives between life sci-
ence companies and public payers (not only private payers) to
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arise at the regional, national and international levels. With
the emergence of pan-European programs, like SEED, it is
also expected that early dialogues with payers will become
more transparent and systemized, which will lead to prompter
market access of new therapeutic and diagnostic products.
These and other topics are subject to our future scientific
research.
Outlook and expert recommendations
Current paper conform with the PPPM objectives summarized
in the EPMAWhite Paper 2012 [48] to support personalized
medicine to be widely adopted in clinical set to yield safer,
more effective, and less expensive medical interventions [39]
and provide stakeholders with evidence of its clinical, cost-
effectiveness, and financial viability. Personalized medicine
raise investors’ interest and expectations and desires who pro-
vide the required capital. Ultimately, the big pharmaceutical
industry has been dithering to receive a personalized medicine
approach as it was expected that patient stratification would
prompt drastically diminishedmarket sizes [48, 49]. However,
there is evidence that personalized medicine, based on bio-
markers, may demonstrate superior effectiveness that warrants
higher pricing. Many new personalized medicines can be ex-
pected to be cost-effective because of the increased clinical
effect, even if they have premium prices. On the other hand, in
many countries, to link reimbursement to cost-effectiveness
via clear dialogue between the commercial and scientific
groups become a common practice ensuring a “right culture”
for promoting truth-seeking rather than progression-seeking
behavior [50] for differentiated and reimbursable medicine,
including important elements, like market opportunity, scien-
tific understanding and unmet medical needs, evaluating risk,
and probability of technical and regulatory success. The recent
massive resources devoted to genome-sequencing studies par-
adoxically provided very little new evidence. However, a bet-
ter strategy for identifying new treatment options may be to
develop methods for analyzing the signaling networks that
underlie disease development, progression, and therapeutic
[51–53]. National and international granting strategies in
PPPM are constantly discussed by European initiative, such
as EPMA [54], pilot programs to support prospective
healthcare have already been set. Since its very beginning,
EPMA is systematically working on the economy of PPPM
[4, 44, 48, 52, 54–58].
Potential problems/limitations of implementation personal-
ized medicine approach, which still faces an uncertain future,
since being addressing prevention rather than targeted therapy,
is more expensive than existing successful preventive inter-
ventions [59–61]. Personalized medicine affecting the costs of
medical care alters the future of the entire healthcare system
and has suggested that medical care costs will be reduced in
the future. Another challenge for implementing personalized
medicine in low- and middle-income countries (LMICs) [60]
is the lack of awareness of needs for personalized medicine
among the general population, low educational level (overall
literacy rates for many LMICs less than 67%), however this
statement might be is stereotyped—e.g., Ukraine is formally
LMIC, but demonstrate rather high educational level of
population.
We suggest the further studies on the following points:
& the development of new methods and measures for im-
proved economic evaluation and efficiency measures in
the health sector to gain advances in increasing value,
promote health-seeking behaviors;
& strategic planning for reimbursement, the output of new
products on the market and patient access to innovations
on all stages—development predictive markers for pa-
tients stratification, personalized treatments, and preven-
tion and beyond;
& avoid overusing unnecessary clinical diagnostic, screen-
ing, and therapeutical interventions that lack sufficient ev-
idence on efficacy and safety via value-guided approach;
& develop multicriteria models for valuing medicines [62];
& to organize relevant clinical trials to search the evidence,
comparative effectiveness research (CER) using popula-
tion-based, retrospective data can inform assessments of
personalized medicine, including implementation of N-of-
1 trials [63];
& the development educational programs in compliance
with experts in medical fields consider ethical issues to
balance involvement of big pharmacology companies
& adaptation of National medical legislation; political sup-
port will likewise be expected to help for accomplishing
normal repayment amongst suppliers and payers, so that
forthcoming consideration can satisfy its guarantee of be-
ing the cost-effective medical model to improve national
health systems;
& adhere the medical legislation in developing countries to
meet requirements of novel and effective models;
& to involve small companies which have higher R&D pro-
ductivity compared with larger companies [64];
& to develop applicable business models for LMICs for re-
duction in health disparities between resource-rich coun-
tries and LMICs;
& further research is needed to develop the models to boost
the reimbursement policy for effective nonpharmacological
approaches, like physical therapy, pain management,
musculoskeletal ultrasound-guided interventions [65, 66],
treatments via probiotics, personalized diets [67], and
regenerative medicine, which recently demonstrated high
level of efficacy and safety [68];
& consider ethical issues, security, and privacy of medical
and financial information [56];
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& implementation of personalized approach should be done
smoothly via development accessible healthcare and
National medical economy and updated legislation for in-
clusive, innovative and reflective societies [69].
AHA, American Heart Association; ASCO, American
Society of Clinical Oncology; CE, Conformité Européenne;
CED, Coverage with Evidence Development; CMS, Centers
for Medicare & Medicaid Services; EC, European
Commission; EMA, European Medicines Agency; FDA, Food
and Drug Administration; HAS, Haute Autorité de Santé; HTA,
health technology assessment; IQWIG, Institute for Quality and
Efficiency in Health Care; NHS, National Health Service;
NICE, National Institute for Health and Care Excellence;
RSA, risk-sharing agreements; SEED, Shaping European
Early Dialogue; LMIC, low- and middle-income countries.
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